That statement is both right and wrong. OmniCar is Car-T, in that T cells are enhanced (if you like) to enable them to hunt down and destroy cancer cells. What makes OmniCar next gen, is the manner in which this happens.
Current Car-T just remove blood, modify T cells, and return blood. This treatment is very expensive running at about $USD 500k per patient. These enhanced T-cells go to work quickly and with vigor, with Kilograms of tumor being destroyed in a very short time span. But this also causes some of the problem. Its action is very destressing to the patient, requiring intensive care treatment for the month while these T-cells do there work. So its not for use on frail patients etc. It also can destroy good tissue by accident. But efficacy is measured above 97%. CHM have found a way using Car-T against solid tumor, and this is a very new development, as all present use is for blood cancer only. Getting it to work on solid tumor is big news, and where the value of CHM is coming from. CHM also seem to have targeted their T-cells to a certain cancer type, also better than the original more broad spectrum T-cell approach. But once they re-introduce the T-cells, they can not control them.
OmniCar enhances the T-cells in a different way. Patient blood is still removed and modified and then returned. But it is treated in a different way. It has found a way of turning the enhancement of T-cells on and off. So initial T-cell treatment is Part A, and when ready the doctors inject part B to make it work. By being able to do this doctors are better able to control the treatment, meaning it will be available to more patients, even the frail, and the need for intensive care treatment will be reduced significantly. Not only can the T-cells be controlled with when to work, but they can also be better armed to attack a certain type of cancer. So all in all, a gentler and more effective treatment. And, if we believe what PTX have been saying, a treatment with considerable cost benefits as well.
So to think about it simply, OmniCar is the vehicle for arming and controlling the T-cells. The cell development work they have been doing, is the work on the cells that the T-cells will be armed with. So whereas Car-T today is used for only blood cancer. And where CHM will be used for Brain cancer. OmniCar can be used on multiple cancer types, and on a greater range of patients (due to the gentler treatment).
Yes CHM is further along in its development path, but it is following a path already traveled. OnmiCar is taking a new path, that looks pretty exciting. It has yet to get its product to the clinic (2023) but it is a generation ahead of its peers. But it appears to be backwards compatible, where other Car-T products can be made OmniCar compatible, this is where the potential licensing exists.
I hold both CHM and PTX so am biased towards both.
As Wasa and others have been saying, OmniCar is just part of the PTX pipeline. PTX 100 and PTX 200 are also company makers all by themselves. Hopefully some updates with respect these two soonish. PTX is doing an basket trial against 5 different cancer types!
https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP5w%2B0yRCZsONhke92GA%3D%3DThis presentation is a good description of Car-T and OmniCar.
